Sirtex's SIRFLOX future

Its current business is growing at over 20% a year, but a pending clinical trial could see this accelerate. Jason Prowd ponders the future of this liver cancer treatment provider.

Sirtex Medical is an anomaly. Unlike many of its biotechnology peers it has a product being sold in the market, it produces positive cash flow, and it pays dividends. It’s no mature business, though, with plans to expand its pool of potential patients via clinical studies. It’s with this ‘I can have my cake and eat it too’ dynamic in mind that I headed along to yesterday’s company briefing.


SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

Related Articles